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Edited by Felix WielandAbstract We undertook a growth-based screen exploiting the
degradation of CTL*, a chimeric membrane-bound ERAD
substrate derived from soluble lumenal CPY*. We screened the
Saccharomyces cerevisiae genomic deletion library containing
5000 viable strains for mutants defective in endoplasmic
reticulum (ER) protein quality control and degradation (ERAD).
Among the new gene products we identiﬁed Yos9p, an ER-
localized protein previously involved in the processing of GPI
anchored proteins. We show that deﬁciency in Yos9p aﬀects the
degradation only of glycosylated ERAD substrates. Degradation
of non-glycosylated substrates is not aﬀected in cells lacking
Yos9p. We propose that Yos9p is a lectin or lectin-like protein
involved in the quality control of N-glycosylated proteins. It may
act sequentially or in concert with the ERAD lectin Htm1p/
Mnl1p (EDEM) to prevent secretion of malfolded glycosylated
proteins and deliver them to the cytosolic ubiquitin-proteasome
machinery for elimination.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Protein degradation; ERAD; Glycoprotein1. Introduction
Secretory proteins enter the endoplasmic reticulum (ER)
through a translocation channel in an unfolded state. Before
delivery to their site of action, proteins are modiﬁed and folded
to acquire their functional conformation [1,2]. Major ER
modiﬁcations include N-linked glycosylation, disulﬁde bond
formation and glycosyl phosphatidyl inositol (GPI)-anchoring
[3,4]. Non-properly folded or orphan proteins are recognized as
such in the ER, retrograde transported back to the cytosol and* Corresponding author. Fax: +49-711-685-4392.
E-mail address: dieter.wolf@ibc.uni-stuttgart.de (D.H. Wolf).
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Abbreviations: CPY, carboxypeptidase Y; CPY*, mutated carboxy-
peptidase Y; CTG*, mutated carboxypeptidase Y transmembrane
domain – GFP; CTL*, mutated carboxypeptidase Y transmembrane
domain – Leu2p; ER, endoplasmic reticulum; ERAD, endoplasmic
reticulum associated degradation; GPI, glycosyl phosphatidyl inositol;
MRH, mannose-6-phosphate receptor homology; PDI, protein disul-
ﬁde isomerase; UPR, unfolded protein response
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process in the ER is controlled by a retention-based quality
control system consisting of ER-resident chaperones, protein
disulﬁde isomerases (PDI), and lectins. This system diﬀerenti-
ates between properly folded proteins and incompletely folded,
potentially cell damaging conformers and decides upon delivery
of proteins to their site of action or retrograde transport to the
cytoplasm for degradation [3,5,9]. N-linked carbohydrate
chains play an essential role in ER-based quality control of se-
cretory proteins. Following co-translational addition of
Glc3Man9GlcNAc2 oligosaccharides to proteins,N-glycans are
matured by stepwise removal of the two terminal glucose resi-
dues by alpha-glucosidases I and II. In mammalian cells, the
resultingGlc1Man9GlcNAc2 structure interacts with the lectins
calnexin and calreticulin, which also bind PDI and participate in
the folding of the protein. Cleavage of the terminal glucose
residue by a-glucosidase II interrupts the lectin interaction al-
lowing properly folded proteins to leave the ER. Incompletely
folded proteins are, instead, recognized by UDP-glucose:gly-
coprotein glucosyltransferase, which adds back a single glucose
residue, thereby allowing a new round of lectin binding and
assisted folding. Proteins unable to acquire their native con-
formation following rounds of deglucosylation-folding-reglu-
cosylation become targets of ER a-mannosidase I, which
releases a mannose residue from the inner branch of the N-
glycan, giving rise to Man8GlcNAc2. It is postulated that pro-
teins containing this oligosaccharide structure are recognized by
another lectin, EDEM in mammalian cells, Htm1/Mnl1p in
yeast, which prevents secretion of the misfolded protein and
initiates the retargeting for retrograde transport into the cytosol
[3,5,9]. Although yeast lacks the re-glucosylating UDP-glu-
cose:glycoprotein glucosyltransferase, the basic machinery for
carbohydrate trimming and recognition of malfolded glyco-
proteins is present and functions like inmammalian cells [10–14].
We have undertaken a genome-wide screen for yeast mu-
tants defective in ER-quality control and associated protein
degradation (ERAD). Using this screen, we recently identiﬁed
Dsk2p and Rad23p as proteins delivering the polyubiquiti-
nated substrate from the trimeric Cdc48-Ufd1-Npl4p complex
to the proteasome [15]. Among the newly discovered proteins
was Yos9p, previously involved in ER-to-Golgi transport of
GPI-anchored proteins [16]. Yos9p is a lumenal, membrane-
associated ER protein with homology to human OS-9 which is
found in all tissues and ampliﬁed in osteosarcomas [17,18].
Yos9p has a mannose-6-phosphate receptor homology domain
of unknown function [18–20]. Here, we show that Yos9p is
required for the ER-associated degradation of N-glycosylated
proteins.ation of European Biochemical Societies.
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2.1. Yeast strains and plasmids
Molecular biological and genetic techniques were carried out using
standard methods [21,22]. S. cerevisiae strains used in this study are
based on W303DC (MATa, ade2-1, can1-100, his3-11 15, leu2-3 112,
trp1-1, ura3-1, prc1D::LEU2) [23]. Cells were grown at 30 C or 38 C
(strains carrying the temperature sensitive sec61-2 allele) in synthetic
complete media. Generation of strain YZK105 (Dprc1Dhtm1) is
described by Z. Kostova and D.H. Wolf, submitted. Strain YBB1 was
generated from strainYZK105 according to Longtine [24] using plasmid
pFA6a-His3MX6 and the primer set 50 yos9del (GATCTTCACA-
TATATCGTTATCATCCCCTTTCTTCCCTGTTTCACGGATCC-
CCGGGTTAATTAA) and 30 yos9del (CAGCTGCTACGTTTG-
TTACCTCCGATTCAGTATTCCCTGTCGAATTCGAGCTCGT-
TTAAAC).
Strains YXL009 (Dprc1Dder3/hrd1) and YBB9 (Dprc1Dyos9) were
obtained by crossing and tetrad dissection of W303DC to YWO0433
(Dder3Dhrd3) and YBB1 to W303-1B [25], respectively.
The prc1-1 insert from bMK150 [23] was subcloned into pRS316 [26]
to express CPY*. Construction of the glycosylation mutant CPY*0000
and of pRS316Gal4-Sec61-2-Leu2p is described by Z. Kostova and
D.H. Wolf, submitted. Plasmid pRS316 expressing Gal4-CTL* was
described by Medicherla et al. [15] and pTV3 expressing Sec61-2::3HA
by Caldwell et al. [27]. For complementation assay, Yos9p was ex-
pressed from pYOS9 based on plasmid pRS313.
2.2. Pulse-chase analysis and immunoprecipitation
Pulse-chase experiments were carried out essentially as described by
Taxis et al. [28]. To follow Sec61-2-HAp degradation, 10 OD cells/time
point were used and cultures were shifted to 38 C for 10 min before
labeling. Microsomal membranes were prepared as described in [29].
Polyclonal CPY [30] and monoclonal HA (Convance) antibodies were
used for immunoprecipitation. Samples were separated by SDS–PAGE
on 8% gels and analyzed using PhosphoImager and ImageQuaNTTM
software.Fig. 1. Model ERAD substrates used in this study and identiﬁcation of
Yos9p as a putative ERAD component involved in the degradation of
glycoproteins. (A) Schematic representation of the ERAD substrates
CPY*, CTL*, CTG*, CPY*0000 and Sec61-2-Leu2p. (B) Isogenic wild
type and mutant cells were plated in serial dilutions on CM medium
with and without leucine. Uracil was also omitted to select for cells
carrying the URA3-based CTL* plasmid. Plates were incubated for 2–
4 days. The leucine auxotrophic WT strain expressing CTL* cannot
grow in the absence of leucine. However, the leucine deﬁciency is
complemented by CTL* in the ERAD defective strains Dder3 and
Dhtm1, and in a strain carrying a deletion of YOS9. Wild type phe-
notype is observed when Yos9p is expressed from plasmid pYOS9 in
Dyos9 cells. (C) Wild type and mutant cells expressing the conditional
non-glycosylated ERAD substrate Sec61-2-Leu2p were plated as de-
scribed in (B) and incubated at 30 C (control) and 38 C for 4–5 days.
Lethality due to leucine deﬁciency is complemented only in the Dder3
strain, indicating that Yos9p, just like Htm1p, does not participate in
the degradation of non-glycosylated substrates.3. Results
We carried out a genome-wide screen using the EURO-
SCARF yeast library consisting of about 5000 Saccharomyces
cerevisiae strains, each deleted for a single non-essential gene
[15], to look for new components involved in protein quality
control and ER-associated degradation. As a ‘‘sensor’’ for
defective ER quality control or degradation, we used the
modular substrate CTL*. CTL* consists of CPY* in the ER
lumen connected to the Leu2 protein (3-isopropylmalate-
dehydrogenase) in the cytoplasm via a transmembrane do-
main (Fig. 1A). Due to recognition of malfolded CPY* in the
ER lumen, the hybrid CTL* protein is retrotranslocated to
the cytosol and readily degraded in wild type cells resulting in
a ‘‘no growth’’ phenotype in leucine-auxotrophic cells incu-
bated in leucine-deﬁcient growth medium. In contrast, leu-
cine-deﬁcient cells can grow on media lacking leucine when a
component of the ER quality control or degradation system is
missing: impaired degradation of CTL* results in comple-
mentation of the leucine deﬁciency. Most of the ERAD-
components known to date, as well as a number of new
potential ERAD players, were recovered from this screen [15].
One of the strains expressing CTL* and capable of growth in
the absence of exogenous leucine supplementation carried a
deletion in YDR057W, encoding the Yos9 protein (Fig. 1B).
CTL* is a derivative of CTG*, a N-glycosylated protein
carrying four carbohydrate chains [31]. To investigate whether
Yos9p is speciﬁcally involved in quality control of glycosy-
lated proteins, we examined the growth of Dyos9 cells ex-
pressing Leu2p fused to the malfolded non-glycosylated ERprotein Sec61-2p [29] (Fig. 1A). Dyos9 cells, as well as cells
defective in the lectin Htm1p/Mnl1p, expressing Sec61-2-
Leu2p are unable to grow at 38 C (Fig. 1C), the restrictive
temperature that induces Sec61-2p unfolding [29]. This con-
ﬁrms that Sec61-2-Leu2p is degraded in Dyos9 and
Dhtm1Dmnl1 cells as in wild type. To substantiate the ﬁnding
that Yos9p is a component of the quality control system for
malfolded ER glycoproteins, we performed pulse-chase mea-
surements with soluble CPY*, membrane-bound CTG*, and
unglycosylated Sec61-2-HAp as ERAD substrates [31,32]. We
found that both CPY* (Fig. 2A) and CTG* (Fig. 2B) deg-
radation is considerably slowed down in cells deﬁcient in
Yos9p. However, there was no observable diﬀerence in turn-
over of Sec61-2-HAp between Dyos9 and wild type cells
(Fig. 2C). As expected [29,33], degradation of Sec61-2-HAp is
substantially inhibited in cells lacking the ubiquitin-protein
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424 B.A. Buschhorn et al. / FEBS Letters 577 (2004) 422–426ligase Der3p/Hrd1p (Fig. 2C). We investigated the contribu-
tion that Yos9p and Htm1p/Mnl1p make to the degradation
of glycosylated CPY*. The stabilization caused by the absence
of Yos9p is slightly, but consistently, greater (10%) than
that caused by deletion of Htm1p/Mnl1p. However, CPY*
degradation is not aﬀected further in the double deletion
Dyos9Dhtm1, indicating that their eﬀects are not additive
(Fig. 3). Finally, we examined the degradation of CPY*0000
(formerly d4CPY*), a CPY* species lacking all four N-gly-R
Time (min)
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0
Fig. 3. Yos9p and Htm1p do not exhibit an additive eﬀect in CPY*
degradation. Degradation of CPY* in wild type (WT), Dyos9, Dhtm1,
and Dhtm1Dyos9 strains of the W303 background was quantiﬁed by
pulse-chase analysis. Absence of Htm1p leads to a stabilization of
35% following a 90 min chase. Deletion of Yos9p alone or, both
of Htm1p and Yos9p results in a slightly higher stabilization (45%) of
CPY* during the same time interval. Data represent the average of
three independent experiments with an average deviation of less than
4% for each time point.cans ([11]; Z. Kostova and D.H. Wolf, submitted). Degra-
dation of this fully unglycosylated CPY* is considerably
delayed in wild type cells (Fig. 4). Deletion of neither Htm1p/
Mnl1p nor Yos9p results in additional stabilization of
CPY*0000, indicating a requirement for carbohydrate chains
on the malfolded protein for Htm1p/Mnl1p or Yos9p action
(Fig. 4).4. Discussion
Yos9p is a protein of unknown function that appears to be
the yeast homolog of the ubiquitous human protein, OS-9. The
function of OS-9 is not well characterized, however, its chro-
mosomal locus lies within a region frequently ampliﬁed in
human sarcomas [17]. The highly conserved rat and mouse
homolog is a peripheral ER protein exposed to the cytoplasm
and associates transiently with the metalloendoproteinase
meprin b, possibly mediating its ER-to-Golgi transport [34].
To date, the only study directly addressing Yos9p function has
been undertaken in yeast in relation to ER-to-Golgi transport
of GPI-anchored proteins [16]. Interestingly, the yeast protein
possesses a carboxy-terminal HDEL ER-retention motif. In
fact, localization studies show that Yos9p is a lumenal glyco-
protein tightly associated with the ER membrane. Yos9p can
be immunoprecipitated with GPI-anchored Gas1p and
Mkc7p. The maturation rate of Gas1p was found to be directlyFig. 2. Degradation of CPY* and CTG* but not of unglycosylated
Sec61-2-HAp is inhibited in the absence of Yos9p. Isogenic wild type
(WT) and yos9 cells each expressing plasmid encoded CPY* (A) or
CTG* (B) were labeled with [35S]methionine and chased for the indi-
cated times. Cell extracts were prepared and subjected to immuno-
precipitation with CPY antibodies. Data represent the average of three
independent experiments with an average deviation of less than 4% for
each time point. (C) Wild type (WT), Dder3, and Dyos9 strains of the
W303 background expressing plasmid encoded Sec61-2-HAp were
shifted to 38 C for 10 min prior to labeling, to induce unfolding of the
substrate. Samples were chased for the indicated times and membrane
fractions were prepared. Sec61-2-HAp was immunoprecipitated with
HA-antibodies. Data represent the average of four independent ex-
periments with an average deviation of 5% for each time point.
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Fig. 4. Deletion of YOS9 does not aﬀect the degradation of ungly-
cosylated CPY*. Pulse-chases analysis reveals no diﬀerence in the
degradation kinetics of CPY*0000 expressed in the isogenic strains
Dyos9, Dhtm1,Dhtm1Dyos9 and wild type. Data represent the average
of three independent experiments with an average deviation of less
than 5% for each time point.
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involvement of Yos9p in GPI-anchored protein processing
[16].
In this study, we show that Yos9p is necessary for eﬃcient
degradation of the glycosylated ERAD substrates CPY* and
CTG*, but plays no role in the degradation of unglycosylated
Sec61-2-HAp (Fig. 2). Moreover, unglycosylated CPY*0000,
whose degradation is already impaired in wild type cells, is not
further aﬀected due to loss of Yos9p (Fig. 4), underscoring the
link between glycosylation and Yos9p function. Like human
OS-9, yeast Yos9p contains a mannose-6-phosphate receptor
homology (MRH) domain, which may play a general role in
N-glycan recognition [20]. A similar domain is found in the b-
subunits of H. sapiens, S. pombe and S. cerevisiae glucosidase
II [20], an enzyme required for ER quality control [4]. We
propose that Yos9p is a lectin with a general role in the ER-
quality control of misfolded N-glycosylated proteins. In fact,
like Htm1p/Mnl1p [12,13], Yos9p is not required for transport
of properly folded glycoproteins such as CPY and invertase,
nor does its absence lead to the unfolded protein response
(UPR) [16].
To date, with the exception of calnexin/calreticulin, the
only other ER-lectin directly associated with ER-quality
control is Htm1/Mnl1p (EDEM in mammals) [12,13,35–37].
Htm1/Mnl1p is believed to recognize the Man8GlcNAc2
degradation signal of improperly folded ER glycoproteins.
Comparison of the degradation kinetics of CPY*0000 in wild
type, Dhtm1, Dyos9, and Dhtm1Dyos9 strains indicates that,
just like Htm1p (Z. Kostova and D.H. Wolf, in preparation),
Yos9p function depends on the presence of glycan chains on
the malfolded substrate (Fig. 4). We also ﬁnd that the action
of Yos9p and Htm1/Mnl1p in ERAD is not additive (Fig. 3).
Loss of Yos9p has a slight, but consistently stronger eﬀect on
CPY* degradation than does the deletion of Htm1/Mnl1p,
although we cannot exclude that this diﬀerence may fall
within the range of experimental error (Fig. 3). One possi-
bility is that Htm1p and Yos9p target the substrate simul-
taneously (with or without a predetermined order), but
recognize diﬀerent glycan-based determinants, therefore act
independent of each other. Alternatively, Htm1p may be
necessary for full Yos9p function, or vice versa (depending on
whether the 10% diﬀerence is statistically signiﬁcant or not).It may also be speculated that Yos9p is part of the delivery
process of the glycosylated substrate to the retrotranslocation
machinery.
The still undeﬁned involvement of Yos9p in GPI anchor
processing does not exclude its participation in ER quality
control of malfolded proteins. It is plausible that Yos9p may
be a dual-function ER-quality control component, like caln-
exin and PDI [3], with a general lectin-chaperone role for
glycosylated malfolded substrates and a more direct role in the
processing or even quality control of GPI-anchored proteins.
Disposal of proteins that fail to become GPI-anchored either
due to the presence of a faulty GPI-anchoring signal or due to
problems in the GPI-anchor assembly pathway seems to occur
via intracellular cytoplasmic degradation with ERAD features
[38,39]. Proteins destined to acquire a GPI-anchor may appear
as malfolded to the ER quality control machinery till they
become attached to the GPI-anchor. Yos9p may be the com-
ponent involved in quality control of GPI-anchor addition.
Recognition and function may lie within the glycans (either on
Yos9p or the substrate, or both) or the mannose-6-phosphate
receptor homology (MRH) domain or a, still, unknown de-
terminant. Studies addressing the multiple aspects of Yos9p
action will broaden our understanding, both of ERAD and
GPI-anchor addition, and reveal the link between these
processes.
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